Pfizer (PFE) Stock Price, News & Analysis

$26.27
-0.05 (-0.19%)
(As of 03:40 PM ET)
Today's Range
$26.04
$26.34
50-Day Range
$25.39
$28.37
52-Week Range
$25.23
$40.37
Volume
15.34 million shs
Average Volume
41.75 million shs
Market Capitalization
$148.75 billion
P/E Ratio
72.97
Dividend Yield
6.40%
Price Target
$36.33

Pfizer MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
38.5% Upside
$36.33 Price Target
Short Interest
Healthy
1.15% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.91
Upright™ Environmental Score
News Sentiment
0.56mentions of Pfizer in the last 14 days
Based on 36 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
23.66%
From $2.24 to $2.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Medical Sector

4th out of 909 stocks

Pharmaceutical Preparations Industry

2nd out of 423 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

PFE Stock Price History

PFE Stock News Headlines

4 Dividend Aristocrats Trading at a Discount
The first quarter of the year was a success for investors. The overall market NYSE: SPY surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI.
4 Dividend Aristocrats Trading at a Discount (PFE)
Near the end of the first quarter, a shift toward more defensive sectors occurred, prompting investors to buy fair-value dividend stocks like MO, T, F, and PFE
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (PFE)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Pfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
EU regulators approve Pfizer antibiotic Emblaveo
Pfizer (NYSE:PFE) Trading 0.9% Higher
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/1 Dividend
1/25/2024
Last Earnings
1/30/2024
Dividend Payable
3/01/2024
Today
4/24/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$36.33
High Stock Price Target
$50.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+38.0%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
1.81%

Debt

Sales & Book Value

Annual Sales
$58.50 billion
Cash Flow
$3.01 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,662,540,000
Free Float
5,659,144,000
Market Cap
$149.04 billion
Optionable
Optionable
Beta
0.61

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer's recent developments in COVID-19 prevention and treatment, including products like Comirnaty and Paxlovid, showcase the company's commitment to innovation in high-demand areas.
  • The company's strong presence in the biopharmaceutical industry, with a diverse portfolio covering therapeutic areas like cardiovascular, metabolic, and infectious diseases, provides a stable revenue stream.
  • Pfizer's strategic acquisitions and partnerships enhance its product pipeline and market reach, contributing to potential future growth.
  • With a market cap of $156.85 billion and a solid financial position indicated by a current ratio of 0.91 and a quick ratio of 0.69, Pfizer offers stability and resilience in uncertain market conditions.
  • Despite recent fluctuations, Pfizer's stock price at $27.70 presents a potential buying opportunity for investors looking to enter at a relatively lower valuation.

Cons

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • The company's P/E ratio of 76.94 and P/E/G ratio of 1.24 suggest that the stock may be currently overvalued compared to its growth prospects, potentially limiting short-term gains.
  • Pfizer's 12-month high of $42.22 and 12-month low of $25.61 indicate price volatility, which could lead to uncertainty for investors seeking stable returns.
  • While Pfizer has a strong institutional investor base, with 68.36% ownership, heavy institutional presence may limit significant price movements based on retail investor sentiment.
  • Competitive pressures in the biopharmaceutical industry and regulatory challenges could impact Pfizer's product development pipeline and market positioning, affecting long-term growth potential.
  • Investors should consider the impact of macroeconomic factors, such as interest rate changes and global health crises, on Pfizer's stock performance and overall market sentiment.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

PFE Stock Analysis - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings
or view top-rated stocks.

What is Pfizer's stock price target for 2024?

16 Wall Street analysts have issued twelve-month target prices for Pfizer's shares. Their PFE share price targets range from $27.00 to $50.00. On average, they predict the company's stock price to reach $36.33 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price.
View analysts price targets for PFE
or view top-rated stocks among Wall Street analysts.

How have PFE shares performed in 2024?

Pfizer's stock was trading at $28.79 at the beginning of the year. Since then, PFE stock has decreased by 8.9% and is now trading at $26.23.
View the best growth stocks for 2024 here
.

When is Pfizer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PFE earnings forecast
.

How can I listen to Pfizer's earnings call?

Pfizer will be holding an earnings conference call on Wednesday, May 1st at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its earnings results on Tuesday, January, 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The biopharmaceutical company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a trailing twelve-month return on equity of 10.88% and a net margin of 3.62%. Pfizer's revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 earnings per share.
Read the conference call transcript
.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, December 14th. Stockholders of record on Friday, January 26th will be paid a dividend of $0.42 per share on Friday, March 1st. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. The ex-dividend date is Thursday, January 25th. This is a positive change from the stock's previous quarterly dividend of $0.41.
Read our dividend analysis for PFE
.

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.68 per share and currently has a dividend yield of 6.40%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 466.67%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, PFE will have a dividend payout ratio of 60.65% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY 2024 earnings guidance on Thursday, February, 1st. The company provided EPS guidance of 2.050-2.250 for the period, compared to the consensus EPS estimate of 2.260. The company issued revenue guidance of $58.5 billion-$61.5 billion, compared to the consensus revenue estimate of $60.5 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.28%), Raymond James & Associates (0.15%), Assenagon Asset Management S.A. (0.11%), Fifth Third Bancorp (0.04%), Raymond James Financial Services Advisors Inc. (0.04%) and MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH (0.04%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Scott Gottlieb and William R Carapezzi Jr.
View institutional ownership trends
.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Pfizer have any subsidiaries?
The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
This page (NYSE:PFE) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners